{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:38:37Z","timestamp":1793306317817,"version":"4.5.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T00:00:00Z","timestamp":1418774400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0113465","type":"journal-article","created":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T09:16:26Z","timestamp":1418894186000},"page":"e113465","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01040715","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Patrick","family":"Durez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vandepapeliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoaneta","family":"Toncheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Kehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Mociran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dhellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Fanget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Ouary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Grouard-Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christophe","family":"Boissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"DL Scott","year":"2010","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"IB McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1478-6354-13-S1-S3","article-title":"Understanding emerging treatment paradigms in rheumatoid arthritis","volume":"13","author":"FC Breedveld","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000289205","article-title":"The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions","volume":"11","author":"PP Sfikakis","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish","volume":"62","author":"ML Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2165\/00019053-200826100-00004","article-title":"Quality-of-life assessment in rheumatoid arthritis","volume":"26","author":"AS Russell","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review","volume":"11","author":"A Rubbert-Roth","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"PA Van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jbspin.2011.11.004","article-title":"Should anti-TNF-\u03b1 drug levels and\/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?","volume":"79","author":"D Mulleman","year":"2012","journal-title":"Joint Bone Spine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14712598.2011.566856","article-title":"Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis","volume":"11","author":"L Semerano","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.4049\/jimmunol.1003372","article-title":"Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis","volume":"186","author":"J Biton","year":"2011","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0968-4328(99)00036-0","article-title":"Keyhole limpet hemocyanin (KLH): a biomedical review","volume":"30","author":"JR Harris","year":"1999","journal-title":"Micron"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"19442","DOI":"10.1073\/pnas.0604827103","article-title":"TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation","volume":"103","author":"H Le Buanec","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1472-6793-7-13","article-title":"An extensive phenotypic characterization of the hTNFalpha transgenic mice","volume":"7","author":"MD Hayward","year":"2007","journal-title":"BMC Physiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/ard.2007.079137","article-title":"Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha","volume":"67","author":"L Delavall\u00e9e","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"R195","DOI":"10.1186\/ar2897","article-title":"Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis","volume":"11","author":"L Delavall\u00e9e","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(11)60501-5","article-title":"Safety, Immunogenicity and Clinical Phase I-II Results of TNF\u03b1-Kinoid Immunotherapeutic in Crohn\u2019s Disease Patients","volume":"140","author":"P Vandepapeliere","year":"2011","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0022-1759(84)90147-9","article-title":"Comparison of in vitro cell cytotoxic assays for tumor necrosis factor","volume":"68","author":"DA Flick","year":"1984","journal-title":"J Immunol Methods"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"D Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"AM Van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jbspin.2011.04.008","article-title":"Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI","volume":"79","author":"C Gaujoux-Viala","year":"2012","journal-title":"Joint Bone Spine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon \u03b1-kinoid","volume":"65","author":"BR Lauwerys","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.4049\/jimmunol.178.11.7450","article-title":"A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis","volume":"178","author":"G Spohn","year":"2007","journal-title":"J Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000076441","article-title":"Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases","volume":"133","author":"C Zuany-Amorim","year":"2004","journal-title":"Int Arch Allergy Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/sj.bjc.6601670","article-title":"TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model","volume":"90","author":"AM Waterston","year":"2004","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.152.2.361","article-title":"Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates","volume":"152","author":"R Schneerson","year":"1980","journal-title":"J Exp Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.5588\/ijtld.12.0111","article-title":"Screening for latent tuberculosis in anti-TNF-\u03b1 candidate patients in a high tuberculosis incidence setting","volume":"16","author":"N Saidenberg-Kermanac\u2019h","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cei.12040","article-title":"Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-\u03b1 immunotherapy in human TNF-\u03b1 transgenic mice depends on anti-TNF-\u03b1 antibody levels","volume":"172","author":"L Semerano","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"ref30","unstructured":"Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, <etal>et al<\/etal>.<bold>.<\/bold> (2013) Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014 Jan 15. doi:[]<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-204714.Epubaheadofprint\" xlink:type=\"simple\">10.1136\/annrheumdis-2013-204714. [Epub ahead of print]<\/ext-link>."},{"key":"ref31","first-page":"954","article-title":"Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases","volume":"31","author":"FR Spinelli","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0113465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T01:26:48Z","timestamp":1598578008000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0113465"}},"subtitle":[],"editor":[{"given":"Hiroyoshi","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0113465","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]}}}